[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509735":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":56,"collaborators":58,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":20,"enrollmentInfo":71,"targetDuration":20,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pre-operative hypofractionated proton therapy","EXPERIMENTAL","Patients will have 5 fractions of proton therapy prior to surgical resection of their sarcoma.",[13],"Radiation: hypofractionation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","hypofractionation","This study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Curtland Deville, MD","Johns Hopkins School of Medicine","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Curtiland Deville, MD","CONTACT","202-537-4788","cdeville@jhmi.edu",{"name":33,"role":29,"phone":20,"phoneExt":20,"email":34},"Ryan Manuel","rmanuel5@jhmi.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Sibley Memorial Hospital","RECRUITING","Washington D.C.","District of Columbia","20016","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-77.03637,38.89511,{"lat":48,"lon":47},[51,52],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},{"name":53,"role":29,"phone":54,"phoneExt":20,"email":55},"Dana Kaplin","410-614-3950","dkaplin1@jhmi.edu",{"type":57,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[59],{"name":60,"class":6},"Robert L. Sloan Fund for Cancer Research","100509735","pre-operative-hypofractionated-proton-therapy-100509735",false,"NCT05917301","Pre-operative Hypofractionated Proton Therapy","PROspective Phase II Trial of Pre-operative Hypofractionated protoN Therapy for Extremity and Truncal Soft Tissue sarcOma","PRONTO","Inclusion Criteria:\n\n* Adult patients (≥18 years of age)\n* Patients with primary or locally recurrent extremity or truncal soft tissue sarcoma\n* WHO\u002FECOG status ≤2\n\nExclusion Criteria:\n\n* History of prior local radiation therapy\n* Inability to tolerate treatment position for duration of simulation or treatment\n* Tumor originating in retroperitoneal location\n* Patients planned for systemic therapy including chemotherapy, targeted agents, and immunotherapy\n* Co-existing malignancy or treated malignancy in the last 2 years expected to limit life expectancy; does not include completely resected cutaneous basal cell carcinoma, squamous cell carcinoma, in situ breast or cervical malignancies, or other pathologies at the discretion of the investigators.\n* Confirmed pregnancy.","ALL","18 Years",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76],"NA","This study is being done to examine whether proton therapy for certain kinds of sarcomas (extremity and trunk soft tissue) is safe and effective. As part of the study, patients will have five fractions of proton therapy before the participants have surgery for the sarcoma. The study will measure wound complications and functional outcomes \u002F quality of life after the procedures.\n\nPatients will be asked to complete questionnaires about the treatment and quality of life from the time of enrollment until about two years after surgery. Otherwise, the participants will have standard of care follow ups with the treatment team.",[79],"Soft Tissue Sarcoma",[81,82,83],"proton therapy","soft tissue sarcoma","hypofractionated","2026-04-15",{"date":86,"type":87},"2026-04-17","ACTUAL",{"date":89,"type":87},"2024-04-18",{"date":91,"type":73},"2032-12",{"name":5,"class":6},1]